Denali Therapeutics Inc
DNLI14.440USD
+1.000+7.44%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
2.10BCap. mercado
PérdidaP/E TTM
Más Datos de Denali Therapeutics Inc Compañía
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Información de la empresa
Símbolo de cotizaciónDNLI
Nombre de la empresaDenali Therapeutics Inc
Fecha de salida a bolsaDec 08, 2017
Director ejecutivoDr. Ryan J. Watts, Ph.D.
Número de empleados422
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 08
Dirección161 Oyster Point Blvd.
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16508668547
Sitio Webhttps://www.denalitherapeutics.com
Símbolo de cotizaciónDNLI
Fecha de salida a bolsaDec 08, 2017
Director ejecutivoDr. Ryan J. Watts, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
768.06K
+20.52%
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Chief Medical Officer, Head of Development
Chief Medical Officer, Head of Development
383.89K
+50.87%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 25 de jul
Actualizado: vie., 25 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
Accionistas
Accionistas
Proporción
Baillie Gifford & Co.
8.32%
The Vanguard Group, Inc.
8.10%
Wellington Management Company, LLP
7.85%
BlackRock Institutional Trust Company, N.A.
6.91%
Fidelity Management & Research Company LLC
5.02%
Other
63.80%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
50.41%
Investment Advisor/Hedge Fund
27.07%
Hedge Fund
10.45%
Individual Investor
4.94%
Corporation
4.93%
Sovereign Wealth Fund
4.42%
Research Firm
2.34%
Pension Fund
0.51%
Bank and Trust
0.30%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
524
153.35M
105.55%
-12.15M
2025Q1
537
151.12M
104.03%
-14.77M
2024Q4
523
145.56M
100.28%
-21.13M
2024Q3
518
152.07M
106.51%
-14.19M
2024Q2
504
147.18M
103.45%
-5.80M
2024Q1
491
145.33M
102.36%
+2.75M
2023Q4
499
138.06M
99.94%
+3.21M
2023Q3
492
132.50M
96.48%
-2.55M
2023Q2
504
131.32M
95.95%
-3.31M
2023Q1
503
131.21M
95.98%
-630.06K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baillie Gifford & Co.
12.09M
8.32%
-223.89K
-1.82%
Mar 31, 2025
The Vanguard Group, Inc.
11.77M
8.1%
-221.47K
-1.85%
Mar 31, 2025
Wellington Management Company, LLP
11.41M
7.85%
+1.56M
+15.86%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.04M
6.91%
-56.41K
-0.56%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.29M
5.02%
-712.15K
-8.90%
Mar 31, 2025
Biogen Inc
7.16M
4.93%
-5.60M
-43.89%
Oct 30, 2024
Temasek Holdings Pte. Ltd.
5.36M
3.69%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
4.88M
3.36%
+1.49M
+43.92%
Mar 31, 2025
Capital Research Global Investors
4.77M
3.28%
-712.07K
-13.00%
Mar 31, 2025
State Street Global Advisors (US)
4.46M
3.07%
-84.22K
-1.85%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
4.17%
Tema Neuroscience and Mental Health ETF
2.07%
ALPS Medical Breakthroughs ETF
1.37%
Global X Guru Index ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
0.84%
BNY Mellon Innovators ETF
0.47%
SPDR S&P Biotech ETF
0.43%
Global X Aging Population ETF
0.33%
iShares Health Innovation Active ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción4.17%
Tema Neuroscience and Mental Health ETF
Proporción2.07%
ALPS Medical Breakthroughs ETF
Proporción1.37%
Global X Guru Index ETF
Proporción1.24%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.84%
BNY Mellon Innovators ETF
Proporción0.47%
SPDR S&P Biotech ETF
Proporción0.43%
Global X Aging Population ETF
Proporción0.33%
iShares Health Innovation Active ETF
Proporción0.26%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.25%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
